Published in Int J Mol Sci on September 12, 2017
Regulatory T cells and immune tolerance. Cell (2008) 18.77
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Drug-induced hepatotoxicity. N Engl J Med (2003) 7.11
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 5.48
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology (2010) 5.00
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med (2016) 4.86
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol (2012) 4.04
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med (2011) 3.78
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis (2010) 3.71
Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (2002) 3.64
FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol (2012) 3.57
Meeting report: International Autoimmune Hepatitis Group. Hepatology (1993) 3.27
Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov (2005) 3.23
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol (1993) 2.89
Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev (2012) 2.76
Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology (2013) 2.72
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther (2011) 2.50
Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet (2000) 2.43
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology (2015) 2.43
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut (1997) 2.35
Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol (2010) 2.33
Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology (2014) 2.29
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology (2004) 2.26
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (2010) 2.26
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
Steroid use in acute liver failure. Hepatology (2013) 2.23
MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol (2013) 2.04
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology (2013) 2.02
Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology (2003) 2.01
Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet (2000) 2.01
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol (2010) 1.97
Autoimmune hepatitis in childhood: a 20-year experience. Hepatology (1997) 1.97
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 1.92
Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology (2005) 1.89
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1988) 1.79
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology (2014) 1.75
Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology (2008) 1.69
Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol (2000) 1.64
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest (1989) 1.61
Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology (1997) 1.61
The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther (2007) 1.60
MicroRNAs: novel regulators during the immune response. J Cell Physiol (2009) 1.59
Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol (2006) 1.59
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res (2010) 1.58
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology (2010) 1.58
Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol (2004) 1.57
Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology (1999) 1.56
Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol (2014) 1.55
Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol (2004) 1.54
Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut (2000) 1.53
Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology (2010) 1.51
Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology (2015) 1.47
Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J Clin Invest (2008) 1.44
The natural history of histologically proved drug induced liver disease. Gut (1999) 1.43
The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett (2009) 1.42
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology (2004) 1.35
Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology (2009) 1.35
LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest (1991) 1.34
Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci (2013) 1.31
Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology (2006) 1.31
Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology (2015) 1.30
CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol (2006) 1.25
EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol (2015) 1.23
Randomised trial of steroid therapy in acute liver failure. Report from the European Association for the Study of the Liver (EASL). Gut (1979) 1.23
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci (2010) 1.22
Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology (1988) 1.21
Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology (1991) 1.21
The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol (2007) 1.16
Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med (1988) 1.16
Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology (1997) 1.15
Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev (2000) 1.15
Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.14
Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol (2011) 1.14
A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci (1991) 1.13
Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology (2002) 1.13
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol (2012) 1.12
Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology (2013) 1.10
A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology (2010) 1.10
Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol (2007) 1.10
Genetic regulation of autoimmune disease: BALB/c background TGF-beta 1-deficient mice develop necroinflammatory IFN-gamma-dependent hepatitis. J Immunol (2001) 1.10
Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology (2000) 1.09
Drug-induced liver injury with autoimmune features. Semin Liver Dis (2014) 1.09
Comfrey herb tea and hepatic veno-occlusive disease. Lancet (1989) 1.08
Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther (2006) 1.07
Inflammation and drug idiosyncrasy--is there a connection? J Pharmacol Exp Ther (2003) 1.05
Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology (1999) 1.05